<DOC>
	<DOC>NCT02376036</DOC>
	<brief_summary>The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.</brief_summary>
	<brief_title>Phase 1 Study of MGD010 in Healthy Subjects</brief_title>
	<detailed_description>This is a Phase 1 study to evaluate the safety, tolerability and PK of MGD010, a CD32B x CD79B DART bi-specific antibody-based molecule. This study will be conducted as a double-blind, randomized, placebo controlled, single ascending dose study among healthy subjects.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies, Bispecific</mesh_term>
	<criteria>Between 18 and 50 years of age Body mass index (BMI) of 18 to 30 kg/m2, inclusive Women of childbearing potential; Women who are pregnant or breastfeeding Any significant acute or chronic medical illness Any major surgery within 4 weeks of study drug administration Active or latent tuberculosis (TB) Active or latent Hepatitis B, Hepatitis C or HIV infection History of allergy to monoclonal antibodies, any significant drug allergy (such as anaphylaxis), or hypersensitivity to any components of the test or reference investigational product formulation. Evidence of organ dysfunction or any clinically significant deviation from normal Vaccination with any live vaccine, or use of any prescription drugs, within 4 weeks of study drug administration Known history of infection or exposure to Hepatitis A virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Normal healthy volunteer</keyword>
</DOC>